MedTrace Logo

GNRH Agonist Trigger and Modified Luteal Phase Adding a Bolus of GnRHa at the Time of Implantation: a RCT

NCT03039049 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 328

Last updated 2017-07-07

No results posted yet for this study

Summary

Purpose:The aim of this project is to prospectively determine whether a single dose of GnRH-agonist administered at the time of implantation increases or not the reproductive outcome in patients undergoing in vitro fertilization ( IVF)/ intracytoplasmatic sperm injection(ICSI) triggered by a GnRH-agonist followed by a small bolus of human chorionic gonadotropin (hCG 1500 IU) the day of oocyte retrieval.

Conditions

Interventions

DRUG

Triptorelin 0.1 mg

a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Ibn Rochd

    lead OTHER

Principal Investigators

  • Abdelhamid Benmachiche, M.D · Ibn roch infertility centre, cité boussouf, Constantine Algeria

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • Algeria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03039049 on ClinicalTrials.gov